Replies to post #23337 on MannKind Corp. (MNKD)

[TREND1]

In January 2017, Novo Nordisk announced that Fiasp ® , a faster formulation of insulin aspart, was approved in Europe and Canada.

It is currently undergoing regulatory review in the United States.

The above would compete with AFREZZA.

FROM 10Q

[DownWithPumpers]

Them listing a product on amazon gives there product much more exposure. I like that, so does the market.

Mannkind doesn't have a product on Amazon. That's Fake News.

They said some day they might work with a very small start-up company whose products are sold in Amazon.

There are 37 blood glucose monitors who have sales on Amazon better than One Drop.

Here's the truth: Mannkind announced that some day they might work with the company that sells the 38th most popular blood glucose monitor on Amazon. Currently of course anyone can buy any BGM they want and use it with Afrezza.